These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29178334)
1. Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. Eriksson JA; Wanka C; Burger MC; Urban H; Hartel I; von Renesse J; Harter PN; Mittelbronn M; Steinbach JP; Rieger J J Neurochem; 2018 Feb; 144(4):421-430. PubMed ID: 29178334 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Maher JC; Wangpaichitr M; Savaraj N; Kurtoglu M; Lampidis TJ Mol Cancer Ther; 2007 Feb; 6(2):732-41. PubMed ID: 17308069 [TBL] [Abstract][Full Text] [Related]
3. Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Suganuma K; Miwa H; Imai N; Shikami M; Gotou M; Goto M; Mizuno S; Takahashi M; Yamamoto H; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M Leuk Lymphoma; 2010 Nov; 51(11):2112-9. PubMed ID: 20860495 [TBL] [Abstract][Full Text] [Related]
4. Nodal regulates energy metabolism in glioma cells by inducing expression of hypoxia-inducible factor 1α. Lai JH; Jan HJ; Liu LW; Lee CC; Wang SG; Hueng DY; Cheng YY; Lee HM; Ma HI Neuro Oncol; 2013 Oct; 15(10):1330-41. PubMed ID: 23911596 [TBL] [Abstract][Full Text] [Related]
5. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875 [TBL] [Abstract][Full Text] [Related]
6. Hypersensitization of tumor cells to glycolytic inhibitors. Liu H; Hu YP; Savaraj N; Priebe W; Lampidis TJ Biochemistry; 2001 May; 40(18):5542-7. PubMed ID: 11331019 [TBL] [Abstract][Full Text] [Related]
7. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure. Khaitan D; Chandna S; Dwarakanath SB J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S67-73. PubMed ID: 20009299 [TBL] [Abstract][Full Text] [Related]
8. Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model. Datta K; Lauritzen MH; Merchant M; Jang T; Liu SC; Hurd R; Recht L; Spielman DM PLoS One; 2019; 14(12):e0225313. PubMed ID: 31830049 [TBL] [Abstract][Full Text] [Related]
9. Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab. Wang F; Liao W; Li C; Zhu L Int Immunopharmacol; 2024 Jun; 134():112187. PubMed ID: 38733825 [TBL] [Abstract][Full Text] [Related]
11. Synergistic Anticancer Action of Lysosomal Membrane Permeabilization and Glycolysis Inhibition. Kosic M; Arsikin-Csordas K; Paunovic V; Firestone RA; Ristic B; Mircic A; Petricevic S; Bosnjak M; Zogovic N; Mandic M; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L J Biol Chem; 2016 Oct; 291(44):22936-22948. PubMed ID: 27587392 [TBL] [Abstract][Full Text] [Related]
12. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells. Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437 [TBL] [Abstract][Full Text] [Related]
13. The Acidic Brain-Glycolytic Switch in the Microenvironment of Malignant Glioma. Reuss AM; Groos D; Buchfelder M; Savaskan N Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073734 [TBL] [Abstract][Full Text] [Related]
14. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Sottnik JL; Lori JC; Rose BJ; Thamm DH Clin Exp Metastasis; 2011 Dec; 28(8):865-75. PubMed ID: 21842413 [TBL] [Abstract][Full Text] [Related]
15. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934 [TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept. Yuen CA; Asuthkar S; Guda MR; Tsung AJ; Velpula KK CNS Oncol; 2016; 5(2):101-8. PubMed ID: 26997129 [TBL] [Abstract][Full Text] [Related]
17. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109 [TBL] [Abstract][Full Text] [Related]
18. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230 [TBL] [Abstract][Full Text] [Related]
19. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]